What is the price-to-earnings ratio of Epigenomics?
The price-earnings ratio of Epigenomics is currently 4.34.
Epigenomics P/S 2024
Epigenomics P/S
4.34
Ticker
ECX.DE
ISIN
DE000A3H2184
WKN
A3H218
As of Dec 18, 2024, Epigenomics's P/S ratio stood at 4.34, a 2,793.33% change from the 0.15 P/S ratio recorded in the previous year.
The Epigenomics P/S history
Epigenomics Aktienanalyse
What does Epigenomics do?
Epigenomics AG is a German biotechnology company specializing in the development of diagnostics for the early detection of cancer. The company is headquartered in Berlin and was founded in 1997. Epigenomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Epigenomics's P/S Ratio
Epigenomics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Epigenomics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Epigenomics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Epigenomics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Epigenomics stock
How has the price-earnings ratio of Epigenomics changed compared to last year?
The price-to-earnings ratio of Epigenomics has increased by 2,793.33% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Epigenomics high compared to other companies?
Yes, the price-to-earnings ratio of Epigenomics is high compared to other companies.
How does an increase in the price-earnings ratio of Epigenomics affect the company?
An increase in the price-earnings ratio of Epigenomics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Epigenomics affect the company?
A decrease in the price-earnings ratio of Epigenomics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Epigenomics?
Some factors that influence the price-earnings ratio of Epigenomics are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Epigenomics pay?
Over the past 12 months, Epigenomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Epigenomics is expected to pay a dividend of 0 EUR.
What is the dividend yield of Epigenomics?
The current dividend yield of Epigenomics is .
When does Epigenomics pay dividends?
Epigenomics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Epigenomics?
Epigenomics paid dividends every year for the past 0 years.
What is the dividend of Epigenomics?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Epigenomics located?
Epigenomics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Epigenomics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Epigenomics from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did Epigenomics pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of Epigenomics in the year 2023?
In the year 2023, Epigenomics distributed 0 EUR as dividends.
In which currency does Epigenomics pay out the dividend?
The dividends of Epigenomics are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Epigenomics stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Epigenomics
Our stock analysis for Epigenomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Epigenomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
